Begelomab

Drug Profile

Begelomab

Alternative Names: anti-CD26 begelomab; Begedina; BT 5/9; murine anti-CD26 BT 5/9; SAND-26

Latest Information Update: 22 Aug 2016

Price : $50

At a glance

  • Originator ADIENNE
  • Class Antibodies; Monoclonal antibodies
  • Mechanism of Action CD26 antigen inhibitors; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Graft-versus-host disease

Most Recent Events

  • 04 Jul 2016 ADIENNE withdraws MAA application filed with the EMA for begelomab (0.9 mg/ml) for Graft versus host disease in European Union (IV)
  • 01 Feb 2016 Phase-II/III clinical trials in Graft-versus-host disease in USA, and Switzerland (IV) (NCT02411084)
  • 01 Feb 2016 ADIENNE initiates enrolment in a phase II/III trial in Graft versus host disease in France (NCT02411084)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top